Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Blood Cells Mol Dis. 2015 Oct 27;56(1):62–69. doi: 10.1016/j.bcmd.2015.10.004

Figure 4. Effects of therapeutic candidates on LSD1, BCL11A and KLF1 protein levels in hemoglobinopathy erythroid cells from hemoglobinopathy patients.

Figure 4

A. LSD1 protein in HbE β-thalassemia cells treated with Benserazide, MS275 or SDMB. The ratio of LSD1:β-actin protein is shown below each panel. Each panel designates an immunoblot performed from at least two different patients. Control designates protein in untreated cells from the same subject.

B. BCL11A protein in sickle cell progenitors treated with SB939, in HbE β-thalassemia cells treated with Benserazide or SDMB (left panel). BCL11A protein in cord blood erythroid progenitor cells treated with MS275, SB939, or Benserazide (right panel).

C. KLF-1 protein in erythroid progenitor cells treated with MS275.